Cargando…

Corrigendum to ‘Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review’: [ESMO Open Volume 6, Issue 5, October 2021, 100276]

Detalles Bibliográficos
Autores principales:	Garutti, M., Lambertini, M., Puglisi, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526978/ https://www.ncbi.nlm.nih.gov/pubmed/34655989 http://dx.doi.org/10.1016/j.esmoop.2021.100291

Ejemplares similares

Corrigendum to ‘Remembering Professor José Baselga’: [ESMO Open Volume 6, Issue 3, June 2021, 100121]
por: Tabernero, J.
Publicado: (2021)

Corrigendum to ‘How I treat medullary thyroid cancer’: [ESMO Open Volume 6, Issue 3, June 2021, 100183]
por: Kiesewetter, B., et al.
Publicado: (2022)

Corrigendum to ‘COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC)’ [ESMO Open Volume 6, Issue 3, June 2021, 100165]
por: Bianchi, F., et al.
Publicado: (2021)

Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review
por: Garutti, M., et al.
Publicado: (2021)

Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273]
por: Reck, M., et al.
Publicado: (2021)

Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]
por: Banna, G.L., et al.
Publicado: (2021)

Corrigendum to ‘Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients’: [ESMO Open Volume 6, Issue 2, April 2021, 100081]
por: Richter, R., et al.
Publicado: (2021)

Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]
por: De Angelis, C., et al.
Publicado: (2021)

Corrigendum to ‘Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study’: [ESMO Open Volume 7, Issue 2, April 2022, 100466]
por: Sinn, K., et al.
Publicado: (2022)

Corrigendum to “Investigation of Biofilm Formation and its Association with the Molecular and Clinical Characteristics of Methicillin-resistant Staphylococcus aureus” [Volume 4, Issue 5, October 2013, Pages 225–232]
por: Cha, Jeong-Ok, et al.
Publicado: (2014)

In this Issue: Volume 112, Issue 10, October 2021
Publicado: (2021)

ESMO Open: news in breast cancer 2019
por: Lambertini, Matteo
Publicado: (2020)

Corrigendum to’ Morphine dependence is attenuated by red ginseng extract and ginsenosides Rh2, Rg3, and compound K’ [Journal of Ginseng Research Volume 40, Issue 4, October 2016, Pages 445-452]
por: Yayeh, Taddesse, et al.
Publicado: (2023)

Corrigendum to “How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain”: [ESMO Open, 7 (2022) 100462]
por: Castañeda, A., et al.
Publicado: (2022)

Corrigendum to “Inositol and In Vitro Fertilization with Embryo Transfer”
por: Simi, G., et al.
Publicado: (2019)

Corrigendum to “PRAK-03202: A triple antigen virus-like particle vaccine candidate against SARS CoV-2”[Heliyon 7 (10) (October 2021) e08124]
por: Mazumder, Saumyabrata, et al.
Publicado: (2021)

Corrigendum to “New Issues in the Management of Osteoporosis”
por: Sirola, Joonas, et al.
Publicado: (2017)

Corrigendum to “Central venous disease in hemodialysis patients” [Volume 38, Issue 3, September 2019, Pages 309-317]
por: Park, Hoon Suk, et al.
Publicado: (2020)

From ESMO TAT 2021
por: Killock, David
Publicado: (2021)

From the ESMO Congress 2021
por: Sidaway, Peter
Publicado: (2021)

Corrigendum to: CHEST 2021;160(1):175-186
Publicado: (2023)

ESMO Open special series on new emerging targets in cancer immunotherapy
por: Lambertini, Matteo
Publicado: (2020)

Corrigendum to “Assesment of SARS-CoV-2 infection-in dentists and supporting staff at a university dental hospital in Argentina”. Journal of Oral Biology and Craniofacial Research Volume 11, Issue 2 (2021) Pages 169–173
por: Puia, Sebastian, et al.
Publicado: (2021)

Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152]
por: Koga, Satoko, et al.
Publicado: (2022)

Corrigendum to ‘A More Fitting Approach to Mask Policy’ The American Journal of Medicine, Volume 135, Issue 11 (2022) 1280-1281
por: Levine, Marc
Publicado: (2023)

Corrigendum to “Multiple group membership, social network size, allostatic load and well-being: A mediation analysis” [Volume 151 (December 2021) 110636]
por: Gallagher, Stephen, et al.
Publicado: (2022)

Corrigendum to: Ethical and policy issues raised by uterus transplants
por: O’Donovan, Laura, et al.
Publicado: (2020)

Corrigendum to “Transformer maze for the evaluation of the learning and memory in rodents” [Heliyon 8 (10), (October 2022) e11211]
por: Filatova, Elena
Publicado: (2022)

Corrigendum to “Middle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea, 2015” [Volume 6, Issue 4, August 2015, 269–278]
Publicado: (2016)

Corrigendum to “Self-isolation” [J. Math. Econom. 93 (2021) 102483]
por: Baril-Tremblay, Dominique, et al.
Publicado: (2022)

ESMO 2021—highlights in colorectal cancer
por: Weiss, Lukas
Publicado: (2022)

Corrigendum to ``Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats'' [Current Therapeutic Research Volume 95, 2021, 100647]
por: Shalaby, Mohammed Fouad, et al.
Publicado: (2022)

CORRIGENDUM to The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma
Publicado: (2019)

Patient Selection for Bronchoscopic Lung Volume Reduction [Corrigendum]
Publicado: (2020)

Corrigendum: Estimation of C. elegans cell- and tissue volumes
Publicado: (2022)

Corrigendum to “Transmission onset distribution of COVID-19” [Int. J. Infect. Dis. 99(October) (2020) 403–407]
por: Chun, June Young, et al.
Publicado: (2021)

Corrigendum to “Quality of Life and Sexual Health in the Aging of PCa Survivors”
por: Gacci, Mauro, et al.
Publicado: (2015)

Corrigendum to “Personal protective equipment and intensive care unit healthcare worker safety in the COVID-19 Era (PPE-SAFE): An international survey” [Journal of Critical Care, Volume 59, October 2020, Pages 70–75]
por: Tabah, Alexis, et al.
Publicado: (2021)

Corrigendum to “The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management” [Thromb. Res., 194, October 2020, Pages 101–115]
por: Abou-Ismail, Mouhamed Yazan, et al.
Publicado: (2021)

Corrigendum to “The development of coronaphobia scale and psychometric effect among UAE people” [Heliyon 8(10) (October 2022) e10875]
por: Abdelrahman, Rasha, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uine1t6b128s76ckgk6c9hm6vk